

# Oligomeric Proanthocyanidins (OPCs)

#### Introduction

Oligomeric proanthocyanidins (OPCs) are some of the most abundant polyphenolic substances in the plant kingdom. Proanthocyanidins are an integral part of the human diet, found in high concentrations in fruits such as apple, pear, and grapes, and in chocolate, wine, and tea. OPCs in nutritional supplements are generally extracted from grape seeds or pine bark. Due to potent antioxidant activity, OPCs have been the subject of recent research,

demonstrating anticarcinogenic, anti-inflammatory, antimicrobial, and vasodilatory properties, making them a potentially valuable therapeutic tool for the treatment of a variety of conditions.

Synonyms for oligomeric proanthocyanidins include procyanidins, procyanidolic oligomers (PCOs), leucoanthocyanins, condensed tannins, and pycnogenols, although the latter term is no longer used. Pycnogenol® is the trade name for an OPC extract from the bark of the French maritime pine tree.

Jacques Masquelier of the University of Bordeaux, France, first studied OPCs in depth after reading of explorer Jacques Cartier's 1534 expedition up the St. Lawrence River, in which Cartier's crew, trapped in ice flows and dying of scurvy, survived after Native Americans gave them a tea brewed from the bark and needles of the native pine. Masquelier later postulated the pine constituents contained vitamin C and flavonoids that aided in the crew's recovery. Today, dietary intake of OPCs varies from tens to hundreds of milligrams per day, depending on geographical and seasonal dietary differences.<sup>1</sup>

# **Biochemistry**

Proanthocyanidins are high-molecular weight oligomers or polymers of a basic flavan-3-ol unit, with an average degree of polymerization between 4 and 11. Proanthocyanidin mixtures from grapes are a combination of dimers, trimers, tetramers, oligomers, and polymers. The reducing capacity of OPCs is thought to be proportional to weight concentration rather than the degree of polymerization.<sup>2,3</sup> The polymeric nature of proanthocyanidins is unique among polyphenols; they complex and precipitate proteins and inhibit enzymes involved in vascular tissue degradation. The ability of OPCs to complex proteins is referred to as astringency and is responsible for the "puckery" sensation when tea or red wine comes in contact with saliva and buccal tissue.<sup>4</sup>

#### **Pharmacokinetics**

Human studies of polyphenol absorption are limited and results have varied depending on the structure and solubility of the phenolic compound. Available research has demonstrated the acidic environment of the human stomach does not readily degrade proanthocyanidins; therefore, absorption rates in the upper

gastrointestinal tract are not high. It appears, however, that even the low amounts observed in urine after an oral dose (usually <25 percent of original dose) are enough to significantly increase plasma/serum antioxidant capacity.<sup>5-7</sup> OPCs reaching the colon undergo extensive degradation by the colonic flora. The metabolites and biological properties of this process have not yet been explored, but it has been suggested they may also have direct antioxidant and protective effects on colonic tissue.<sup>3,8</sup>

#### **Mechanisms of Action**

OPCs possess antioxidant, antimutagenic, anticarcinogenic, anti-inflammatory, and antiviral properties.

#### Antioxidant

The potent antioxidative properties of OPCs account for their therapeutic benefit in disease states characterized by oxidative stress. OPCs also demonstrate potent, concentration-dependent, free radical scavenging ability. Studies in mice show OPCs inhibit chemically-induced lipid peroxidation, DNA fragmentation, and subsequent apoptosis (indicators of oxidative tissue damage) in a dose-dependent manner in hepatic and brain tissue. Human studies also demonstrate an antioxidative mechanism as evidenced by decreased lipid peroxidation of LDL cholesterol decreased lipid peroxidation of LDL cholesterol and increased free-radical trapping capacity after consumption of red wine containing OPCs.

OPCs appear to have an affinity for vascular tissue and strongly inhibit several enzymes involved in degradation of collagen, elastin, and hyaluronic acid, the main structural components of the extravascular matrix. These effects are perhaps attributable to trapping reactive oxygen species and preventing oxidative injury to vascular endothelium. *In vitro* studies have also found OPCs increase resistance of cell membranes to injury and degradation. 14,15

Proanthocyanidins possess endothelium-dependent relaxing (EDR) activity in blood vessels by increasing nitric oxide production, <sup>16</sup> and stimulate vascular endothelial growth factor, a signaling factor involved in initiation of wound

healing. OPCs may also protect the microvasculature of the retina and increase visual acuity, possibly by increasing the rate of rhodopsin regeneration.<sup>17-19</sup> In a rabbit model of ischemia/ reperfusion, OPCs' beneficial effects were attributed to binding of copper and iron liberated from myocardial tissue, thereby reducing their oxidative effects.<sup>20</sup> The positive effects of OPCs on microcirculation are also attributed to their inhibition of LDL oxidation11,12,21 and decreased incidence of foam cells, markers of early stage atherosclerosis.<sup>22</sup> Grape seed proanthocyanidins may have a vitamin E-sparing effect.<sup>23</sup> A clinical study of 10 healthy volunteers examining the effect of OPC supplementation on markers of oxidative stress showed significantly increased levels of alpha-tocopherol in red cell membranes.<sup>24</sup>

## **Anti-inflammatory**

OPCs from pine bark decrease symptoms of chronic inflammation. *In vitro* studies demonstrate anti-inflammatory effects may be due to inhibition of peroxide generation by macrophages. <sup>25,26</sup> In addition, animal studies demonstrate OPCs from grape seed significantly inhibit formation of proinflammatory cytokines, interleukin 1-beta, and tumor necrosis factor-alpha. <sup>27</sup>

# Antimutagenic/Anticarcinogenic

OPCs possess natural antimutagenic properties when exposed to certain strains of bacteria. Although the exact mechanism is not known, an *in vitro* study found OPCs exhibit selective cytotoxicity for certain cancerous cell lines, while remaining non-toxic to normal human gastric mucosal cells and macrophages. An *in vitro* study in a mouse skin tumor model demonstrated OPCs inhibition of two markers of tumor promotion.

# Antimicrobial Effects

Flavonoids and associated polyphenols, particularly OPCs, elicit an inhibitory effect on human immunodeficiency virus (HIV). A possible mechanism may be inhibition of gene expression regulating virus binding to cell receptors on normal lymphocytes, thus preventing infection.<sup>31</sup>

#### **Clinical Indications**

# Vascular Conditions: Peripheral Vascular Insufficiency/Lymphedema

Because of affinity of OPCs for vascular tissue, the basal membrane of the skin, and gastrointestinal mucosa, the preponderance of research has focused on conditions affecting these tissues. Europeans use OPCs to treat various vascular disorders, including varicose veins, venous insufficiency, capillary fragility, and retinopathies. Several clinical trials have confirmed the beneficial effects of OPC use in treating vascular disorders. 32-35

A double-blind study of 50 patients with chronic venous insufficiency manifesting as varicose veins revealed 150 mg proanthocyanidins daily for one month had a more rapid and lasting effect on symptom alleviation than 450 mg daily of diosmin (a flavonoid known for its therapeutic efficacy in vascular insufficiency).<sup>32</sup>

A double-blind, placebo-controlled study of 92 patients with peripheral venous insufficiency demonstrated improved venous function at a dose of 300 mg OPCs daily for 28 days. Sixty-nine patients reported 50-percent reduction in clinical parameter scores for pain, paresthesias, nocturnal cramps, and edema. Seventy-five percent of patients felt the treatment was effective, compared to 41 percent of the placebo group.<sup>33</sup>

The use of grape seed OPCs in patients with venous and lymphatic edema was examined in a multicenter study of 165 patients with premenstrual symptoms, including breast tenderness, abdominal swelling, and pelvic pain. Sixty percent of patients reported improvement in, or cessation of, symptoms after initial treatment; when treatment duration doubled, that number increased to 78 percent.<sup>34</sup>

A double-blind, randomized, placebocontrolled study of 63 patients undergoing treatment for lymphedema resulting from breast cancer surgery found six months of OPCs (600 mg daily) was superior to placebo in improving pain, skin tension, and arm and shoulder movements.<sup>35</sup>

#### Skin Conditions

Skin conditions secondary to excessive exposure to ultraviolet rays (UVR) benefit from oral administration of proanthocyanidins. Twentyone volunteer subjects were given 1.10 mg/kg OPCs daily for four weeks followed by 1.66 mg/ kg OPCs daily for a second four-week period. UV sensitivity, expressed as minimal erythema dose (MED), was measured twice prior to OPC supplementation to establish a baseline, and again at the end of each four-week period. The UVR dose required to induce minimal erythema increased significantly (in a dose-dependent manner) in subjects supplemented with OPCs. 36 OPC supplementation at the higher dose resulted in nearly twice the mean baseline MED. Activation of nuclear factor-kappaB is believed to play a key role in UVR-induced erythema.<sup>37</sup>

Melasma is a skin condition characterized by hyperpigmentation of the face and neck and is attributed to UV radiation, genetic factors, pregnancy, and various phototoxic drugs. OPCs from pine bark have been shown to be beneficial in treating melasma in women.<sup>38</sup>

### Cardiovascular Disease

One explanation for the "French Paradox" – relatively low rates of cardiovascular disease in France despite a diet of rich foods – is that OPCs in red wine offer protection by reducing LDL oxidation, inhibiting cyclooxygenase and lipoxygenase in platelets and macrophages, and decreasing thrombotic events.<sup>39</sup> Epidemiological studies support this theory, indicating red wine consumption reduces the incidence of coronary heart disease.<sup>40,41</sup>

Several clinical trials have examined the effect of proanthocyanidins in red wine on lipid peroxidation and cardiovascular disease. In a two-week study of 17 healthy men, nine consumed 400 mL red wine daily with meals, while the remaining eight men consumed the same amount of white wine. Red wine consumption resulted in a 20-percent reduction of lipid peroxidation in plasma, while increased lipid peroxidation was observed in the men who drank white wine, suggesting phenolic substances present in red wine may be

responsible for the observed antioxidant effects. <sup>12</sup> Red wine polyphenols also significantly increase plasma high-density lipoprotein (HDL) cholesterol and plasma apolipoprotein A-I concentrations in humans. <sup>42</sup>

Natella et al investigated the effect of grape seed proanthocyanidins on plasma postprandial oxidative stress. Eight healthy volunteers consumed a lipid-rich test meal with or without OPCs. OPC supplementation resulted in decreased lipid peroxidation, increased plasma antioxidant levels, and improved resistance of LDL to oxidation.<sup>43</sup> A larger, randomized, double-blind, placebo-controlled study of 40 hypercholesterolemic patients examined the effects of supplementation of niacin-bound chromium, grape seed extract, or a combination on total cholesterol, LDL, and autoantibodies to oxidized LDL. Grape seed extract administration did not result in statistically significant improvement in total cholesterol or LDL levels compared to placebo; however, the chromium/ grape seed extract combination resulted in significant improvements in both parameters, superior to results with either substance alone. The group receiving grape seed extract alone demonstrated a greater than 50-percent decrease in autoantibodies to oxidized LDL.21

# Retinopathies/Ophthalmologic Conditions

Numerous clinical trials in France support the protective benefit of OPCs on retinal health. In a randomized, double-blind, placebo-controlled study, 75 patients experiencing visual stress from video-display units were given either an OPC extract from grape seed, a *Vaccinium myrtillus* (bilberry) extract, or placebo. Dosage in all groups was 100 mg three times daily for 60 days. Assessments at trial conclusion showed subjects given either OPCs or bilberry had significant improvement in contrast sensitivity and subjective visual disturbances, compared to placebo. Subjects in the OPC group showed improvement superior to those in the bilberry group.<sup>44</sup>

In additional studies of patients without retinal or ophthalmologic pathologies, proanthocyanidins administered at 150-300 mg

daily for 30-60 days improved visual acuity, contrast sensitivity in patients with ocular stress due to video display unit use, and visual performance after glare exposure.<sup>17,18</sup> In another study 91 patients with bilateral myopia and associated ocular disorders demonstrated 100 mg OPCs given three times daily for 30 days improved retinal sensitivity during dark adaptation in 72 of the patients (79%). Subjective improvement was even greater, with 90 percent of patients reporting symptom improvement.<sup>45</sup> In the case of retinopathy, a review of 26 case studies reveals OPCs significantly improved vascular lesions, microaneurisms, and exudates associated with diabetic retinopathy.<sup>19</sup>

#### Cancer

OPCs incubated with several human cancer cell lines (breast, lung, and gastric) revealed a selective cytotoxicity for the cancerous cells, but not normal gastric mucosal cells or macrophages. It is postulated that in addition to selective cytotoxicity, OPCs may up-regulate certain apoptosis-promoter genes and down-regulate apoptosis-inhibitor genes in cancerous cells.<sup>29</sup>

An *in vitro* study explored the chemopreventive effects of an OPC extract on cultured, non-malignant human Chang liver cells treated with the chemotherapeutic agents idarubicin or 4-hydroxyperoxycyclophasphamide; both agents induce apoptosis in normal cells. Incubation of either chemotherapeutic agent with non-malignant Chang liver cells resulted in growth inhibition significantly reversed with addition of OPC extract.<sup>46</sup> This suggests OPCs could be helpful adjuncts in managing the cytotoxicity of chemotherapeutic agents to normal human cells.

# **HIV Infection**

Grape seed proanthocyanidins elicit an inhibitory effect on HIV infection *in vitro*. Recent research indicates chemokine receptors 3 and 5 expression on Th-2 lymphocytes is a prerequisite for HIV infection of the central nervous system.<sup>47</sup> An OPC extract incubated with immunocompetent peripheral blood mononuclear cells (PBMC) resulted in a significant dose-dependent suppression of HIV-1 chemokine co-receptor gene

expression (chemokine receptors 2b, 3, and 5) in normal PBMC. This inhibition may prevent binding of the HIV virus to cell receptor sites on normal white blood cells, thereby preventing infection.<sup>31</sup>

## **Wound Healing**

Nitric oxide stimulates collagen synthesis and subsequent healing at wound sites. <sup>48,49</sup> In addition, the induction of vascular endothelial growth factor (VEGF) is a crucial step in the reepithelialization phase of skin repair. <sup>50,51</sup> Extracts of grape seed proanthocyanidins appear to stimulate the expression of VEGF in cultured keratinocytes, making OPCs a potential therapeutic tool in dermal wound healing. <sup>52,53</sup>

#### Insulin Resistance

Preliminary research in animals indicates OPCs may have potential in the treatment of insulin resistance. A short-term study in rats revealed grape seed extract decreased circulating insulin levels and systolic blood pressure. A one-year study also revealed significantly lower glycosylated hemoglobin levels in animals receiving a combination of grape seed extract, niacin-bound chromium, and a zinc methionine complex, compared to controls, although the effects of the single ingredients were not evaluated. 54-56

# **Protection from Drug Toxicity**

Animal studies indicate OPC administration is beneficial in preventing hepatic and renal toxicity in instances of acetaminophen and other drug poisonings. This protection may be attributable to detoxification of cytotoxic free radicals or facilitation of DNA repair. <sup>57,58</sup> A study in rats with experimentally-induced myoglobinuric acute renal failure showed OPC administration to be of benefit in reducing blood urea nitrogen and serum creatinine; histological improvement was also noted. <sup>59</sup>

#### **Pancreatitis**

A daily dose of 200-300 mg of a grape seed extract was given to three patients with chronic pancreatitis, characterized by epigastric pain with radiation to the back. All three patients reported a significant reduction in pain severity and frequency of painful episodes, and two of three patients reported a significant reduction in use of narcotic analgesics. The third patient, vomiting almost daily, reported resolution of vomiting after taking the OPC extract. All three patients reported a return of symptoms upon cessation of treatment.<sup>60</sup>

# Attention Deficit/Hyperactivity Disorder (ADHD) and Cognitive Dysfunction

Anecdotal reports of OPC use in ADHD describe improvement in symptoms that worsened upon discontinuation of treatment and improved again when treatment was restarted. <sup>61,62</sup> In a study of age-accelerated mice, oral dosing of an OPC extract for two months resulted in significant improvement in age-related memory decline and learning impairments. <sup>63</sup>

# Systemic Lupus Erythematosus

In a pilot study of 11 patients with systemic lupus erythematosus (SLE), six were given an OPC extract (120 mg daily for 30 days, then 60 mg daily for 30 days) in addition to usual medications; the other five patients received placebo with their usual medications. Patients in the treatment group showed reductions in spontaneous lymphocyte apoptosis, T-lymphocyte activation, reduced generation of reactive oxygen species, lower erythrocyte sedimentation rates, and a decrease in the SLE disease activity index compared to the placebo group. The mechanism may be attributable to OPCs' antioxidant effect, resulting in reduced inflammatory activity.<sup>64</sup>

#### Asthma

In a pilot study of 26 patients with varying degrees of asthma severity, an OPC dosage of 1 mg/lb/day for four weeks, at which time patients in the treatment group were crossed over to the placebo group for another four weeks, resulted in statistically significant improvements in forced expiratory volume (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratios. A significant reduction in serum leukotriene levels was also observed in patients receiving OPCs when compared to control and baseline values, and patients in the OPC group reported significant improvements in asthma symptom scores.<sup>65</sup>

## **Drug Interactions**

There are no known interactions between OPC extracts and other medications; however, data from *in vitro* and human studies indicate OPCs have an inhibitory effect on platelet aggregation similar to aspirin. <sup>66,67</sup> Therefore, caution is suggested in patients taking anticoagulant medication.

# **Side Effects and Toxicity**

OPCs have an excellent safety profile, with no known side effects, toxicity, or drug interactions. Rat studies have demonstrated OPCs to be nonmutagenic and nontoxic at high levels. The no-observed-adverse-effect level (NOAEL) of a chronic toxicity study of grape seed extract in rats was 1400-1500 mg/kg body wt/day,<sup>68</sup> which translates to 93-100 g grape seed extract daily for an average 150-pound adult. Human safety and toxicity studies for OPCs are limited, but no side effects are reported in the literature.

# **Dosage**

Suggested dosages for OPCs generally range from 50-150 mg daily, although in some studies dosages of 300 mg daily were used. A dosage of 1 mg/kg/body wt has also been suggested.

#### References

- Murray M, Pizzorno J. Procyanidolic oligomers. In: Murray M, Pizzorno J, eds. *The Textbook of Natural Medicine*. 2<sup>nd</sup> ed. London, England: Churchill Livingston; 1999:899-902.
- 2. Santos-Buelga C, Scalbert A. Proanthocyanidins and tannin-like compounds: nature, occurrence, dietary intake and effects on nutrition and health. *J Food Sci Agric* 2000;80:1094.
- 3. Scalbert A, DËprez S, Mila I, et al. Proanthocyanidins and human health: systemic effects and local effects in the gut. *Biofactors* 2000;13:115-120.
- 4. Baxter NJ, Lilley TH, Haslam E, Williamson MP. Multiple interactions between polyphenols and a salivary proline-rich protein repeat result in complexation and precipitation. *Biochemistry* 1997;36:5566-5577.
- 5. Duthie GG, Pedersen MW, Gardner PT, et al. The effect of whiskey and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. *Eur J Clin Nutr* 1998;52:733-736.
- 6. Whitehead TP, Robinson D, Allaway S, et al. Effect of red wine ingestion on the antioxidant capacity of serum. *Clin Chem* 1995;41:32-35.
- Serafini M, Maiani G, Ferro-Luzzi A. Alcoholfree red wine enhances plasma antioxidant capacity in humans. *J Nutr* 1998;128:1003-1007.
- 8. Bokkenheuser VD, Shackleton CH, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. *Biochem J* 1987;248:953-956.
- 9. Bagchi D, Garg A, Krohn RL, et al. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract *in vitro*. *Res Commun Mol Pathol Pharmacol* 1997;95:179-189.
- Bagchi D, Garg A, Krohn RL, et al. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. *Gen Pharmacol* 1998;30:771-776.
- Natella F, Belelli F, Gentili V, et al. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. J Agric Food Chem 2002;50:7720-7725.

- 12. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. *Am J Clin Nutr* 1995;61:549-554.
- 13. Maffei Facino R, Carini M, Aldini G, et al. Free radicals scavenging action and antienzyme activities of procyanidines from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung* 1994;44:592-601.
- 14. Gavignet C, Groult N, Godeau G, et al. Effect of procyanidolic oligomers on cultured mesenchymal cells. I. Effect on attachment, proliferation and detachment of cells. *Pathol Biol (Paris)* 1989;37:746-753. [Article in French]
- 15. Robert AM, Groult N, Six C, Robert L. The effect of procyanidolic oligomers on mesenchymal cells in culture. II. Attachment of elastic fibers to the cells. *Pathol Biol (Paris)* 1990;38:601-607. [Article in French]
- Fitzpatrick DF, Fleming RC, Bing B, et al. Isolation and characterization of endotheliumdependent vasorelaxing compounds from grape seeds. *J Agric Food Chem* 2000;48:6384-6390.
- 17. Corbe C, Boissin JP, Siou A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomers (Endotelon). *J Fr Ophtalmol* 1988;11:453-460. [Article in French]
- 18. Boissin JP, Corbe C, Siou A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). *Bull Soc Ophtalmol Fr* 1988;88:173-174, 177-179. [Article in French]
- 19. Froantin M. Procyanidolic oligomers in the treatment of capillary fragility and retinopathy in diabetics. *Med Int* 1981;16:432-434. [Article in French]
- Maffei Facino R, Carini M, Aldini G, et al. Procyanidines from *Vitis vinifera* seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. *Planta Med* 1996;62:495-502.
- 21. Preuss HG, Wallerstedt N, Talpur S, et al. Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. *J Med* 2000;31:227-246.

- 22. Vinson JA, Tuefel K, Wu N. Red wine, dealcoholized red wine, and especially grape juice inhibit atherosclerosis in a hamster model. *Atherosclerosis* 2001;156:67-72.
- 23. Maffei Facino R, Carini M, Aldini G, et al. Sparing effect of procyanidins from *Vitis vinifera* on vitamin E: *in vitro* studies. *Planta Med* 1998:64:343-347.
- 24. Simonetti P, Ciappellano S, Gardana C, et al. Procyanidins from *Vitis vinifera* seeds: *in vivo* effects on oxidative stress. *J Agric Food Chem* 2002;50:6217-6221.
- 25. Bayeta E, Lau B. Pycnogenol inhibits generation of inflammatory mediators in macrophages. *Nutr Res* 2000;20:249-259.
- Blazso G, Gabor M, Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from *Pinus pinaster Ait*. after oral and cutaneous application. *Pharmazie* 1997;52:380-382
- 27. Li WG, Zhang XY, Wu YJ, Tian X. Antiinflammatory effect and mechanism of proanthocyanidins from grape seeds. *Acta Pharmacol Sin* 2001;22:1117-1120.
- 28. Liviero L, Puglisi P. Antimutagenic activity of procyanidins from *Vitis vinifera*. *Fitoterapia* 1994;65:203-209.
- Ye X, Krohn RL, Liu W, et al. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. *Mol Cell Biochem* 1999;196:99-108
- 30. Bomser JA, Singletary KW, Wallig MA, Smith MA. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds. *Cancer Lett* 1999;135:151-157.
- 31. Nair MP, Kandaswami C, Mahajan S, et al. Grape seed extract proanthocyanidins downregulate HIV-1 entry coreceptors, CCR2b, CCR3, and CCR5 gene expression by normal peripheral blood mononuclear cells. *Biol Res* 2002;35:421-431.
- 32. Delacroix P. Double-blind study on Endotelon in chronic venous insufficiency. *Rev Med (Paris)* 1981;1793:27-28.
- 33. Thebaut JF, Thebaut P, Vin F. Study of Endotelon in functional manifestations of peripheral venous insufficiency. Results of a double-blind study on 92 patients. *Gaz Med (Montr)* 1985;92:12.

# Oligomeric Proanthocyanidins

- 34. Amsellem M, Masson JM, Negui B, et al. Endotelon in the treatment of venolymphatic problems in premenstrual syndrome, a multicentered study on 165 patients. *Tempo Med* 1987;November:282. [Article in French]
- 35. Pecking A. Oligomeric proanthocyanidins (Endotelon®) in the treatment of post therapeutic lymphoedema of the upper limbs. *Association de Lymphologyie de Lange* Francaise Hospital Saint-Louis, Paris 1989;69-73. [Article in French]
- 36. Saliou C, Rimbach G, Moini H, et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. *Free Radic Biol Med* 2001;30:154-160.
- Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. *Nature* 1996;379:335-339.
- 38. Ni Z, Mu Y, Gulati O. Treatment of melasma with pycnogenol. *Phytother Res* 2002;16:567-571.
- 39. Frankel EN, Kanner J, German JB, et al. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. *Lancet* 1993;341:454-457.
- 40. Das DK, Sato M, Ray PS, et al. Cardioprotection of red wine: role of polyphenolic antioxidants. *Drugs Exp Clin Res* 1999;25:115-120.
- 41. Sato M, Maulik N, Das DK. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. *Ann N Y Acad Sci* 2002:957:122-135.
- 42. Lavy A, Fuhrman B, Markel A, et al. Effect of dietary supplementation of red or white wine on human blood chemistry, hematology and coagulation: favorable effect of red wine on plasma high-density lipoprotein. *Ann Nutr Metab* 1994;38:287-294.
- 43. Natella F, Belelli F, Gentili V, et al. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. *J Agric Food Chem* 2002;50:7720-7725.
- 44. Fusi L, Czimeg F, Pesce F, et al. Effects of procyanidolic olygomers from *Vitis vinifera* in subjects working at video-display units. *Ann Ottalmol Clin Ocul* 1990;116:575.
- 45. Moriconi S, Bellezza PG. Clinical study on the activity of procyanidolic oligomers of *Vitis vinifera* on retinal sensitivity in myopic patients. *Ann Ottalmol Clin Ocul* 1988;114:585-594.

- 46. Joshi SS, Kuszynski CA, Bagchi M, Bagchi D. Chemopreventive effects of grape seed proanthocyanidin extract on Chang liver cells. *Toxicology* 2000;155:83-90.
- 47. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. *Nature* 1997;385:645-649.
- 48. Witte MB, Thornton FJ, Efron DT, Barbul A. Enhancement of fibroblast collagen synthesis by nitric oxide. *Nitric Oxide* 2000;4:572-582.
- 49. Stallmeyer B, Kampfer H, Kolb N, et al. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely inhibits wound reepithelialization. *J Invest Dermatol* 1999;113:1090-1098.
- 50. Frank S, Stallmeyer B, Kampfer H, et al. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. *FASEB J* 1999;13:2002-2014.
- 51. Most D, Efron DT, Shi HP, et al. Characterization of incisional wound healing in inducible nitric oxide synthase knockout mice. *Surgery* 2002;132:866-876.
- Khanna S, Roy S, Bagchi D, et al. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med 2001;31:38-42.
- 53. Khanna S, Venojarvi M, Roy S, et al. Dermal wound healing properties of redox-active grape seed proanthocyanidins. *Free Radic Biol Med* 2002;33:1089-1096.
- 54. Preuss HG. Effects of glucose/insulin perturbation on aging and chronic disorders of aging; the evidence. *J Am Coll Nutr* 1997;16:397-403.
- 55. Preuss HG, Montamarry S, Echard B, et al. Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats. *Mol Cell Biochem* 2001;223:95-102.
- Preuss HG, Bagchi D, Bagchi M. Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X. Ann NY Acad Sci 2002;957:250-259
- 57. Ray SD, Patel D, Wong V, Bagchi D. *In vivo* protection of DNA damage associated apoptotic and necrotic cell deaths during acetaminopheninduced nephrotoxicity, amiodarone-induced lung toxicity, and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract. *Res Commun Mol Pathol Pharmacol* 2000;107:137-166.

- 58. Bagchi D, Ray SD, Patel D, Bagchi M. Protection against drug- and chemical-induced multiorgan toxicity by a novel IH636 grape seed proanthocyanidin extract. *Drugs Exp Clin Res* 2001;27:3-15.
- 59. Stefanovic V, Savic V, Vlahovic P, et al. Reversal of experimental myoglobinuric acute renal failure with bioflavonoids from seeds of grape. *Ren Fail* 2000;22:255-266.
- 60. Banerjee B, Bagchi D. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract in the treatment of chronic pancreatitis. *Digestion* 2001;63:203-206.
- 61. Heimann SW. Pycnogenol for ADHD? *J Am Acad Child Adolesc Psychiatry* 1999;38:357-358.
- 62. Passwater RA. *All About Pycnogenol*. Garden City Park, NY: Avery Publishing Group; 1999.
- 63. Liu FJ, Zhang YX, Lau BH. Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. *Cell Mol Life Sci* 1998;54:1168-1172.
- 64. Stefanescu M, Matache C, Onu A, et al. Pycnogenol efficacy in the treatment of systemic lupus erythematosus patients. *Phytother Res* 2001;15:698-704.
- Hosseini S, Pishnamazi S, Sadrzadeh SM, et al. Pycnogenol<sup>®</sup> in the management of asthma. *J Med Food* 2001;4:201-209.
- 66. Putter M, Grotemeyer KH, Wurthwein G, et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. *Thromb Res* 1999;95:155-161.
- 67. Yamakoshi J, Saito M, Kataoka S, Kikuchi M. Safety evaluation of proanthocyanidin-rich extract from grape seeds. *Food Chem Toxicol* 2002;40:599-607.
- 68. Chang WC, Hsu FL. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. *Prostaglandins Leukot Essent Fatty Acids* 1989;38:181-188.